日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer

猛禽定位预测雌激素受体阳性乳腺癌的预后和他莫昔芬反应

Josefine Bostner, Anya Alayev, Adi Y Berman, Tommy Fornander, Bo Nordenskjöld, Marina K Holz, Olle Stål

ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer

ERRα 是三阴性乳腺癌对他莫昔芬治疗反应和生存的标志

Subrata Manna, Josefine Bostner, Yang Sun, Lance D Miller, Anya Alayev, Naomi S Schwartz, Elin Lager, Tommy Fornander, Bo Nordenskjöld, Jane J Yu, Olle Stål, Marina K Holz

VAV3 mediates resistance to breast cancer endocrine therapy

VAV3 介导乳腺癌内分泌治疗耐药性

Helena Aguilar, Ander Urruticoechea, Pasi Halonen, Kazuma Kiyotani, Taisei Mushiroda, Xavier Barril, Jordi Serra-Musach, Abul Islam, Livia Caizzi, Luciano Di Croce, Ekaterina Nevedomskaya, Wilbert Zwart, Josefine Bostner, Elin Karlsson, Gizeh Pérez Tenorio, Tommy Fornander, Dennis C Sgroi, Rafael Ga

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials

mTOR效应因子4EBP1和S6K2经常共表达,且与乳腺癌预后不良和内分泌耐药相关:一项纳入斯德哥尔摩随机他莫昔芬试验患者的回顾性研究

Karlsson, Elin; Pérez-Tenorio, Gizeh; Amin, Risul; Bostner, Josefine; Skoog, Lambert; Fornander, Tommy; Sgroi, Dennis C; Nordenskjöld, Bo; Hallbeck, Anna-Lotta; Stål, Olle

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit

Akt、mTOR 和雌激素受体的激活可作为预测他莫昔芬治疗疗效的特征。

Bostner, Josefine; Karlsson, Elin; Pandiyan, Muneeswaran J; Westman, Hanna; Skoog, Lambert; Fornander, Tommy; Nordenskjöld, Bo; Stål, Olle